Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma
Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid · 2026
Read Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma by Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13462186.txt.
Description
Sohaib Irfan and co-authors priced an ongoing antibody combo against a one time cell therapy for relapsed multiple myeloma, asking American payers which buys health more cheaply. The teclistamab plus daratumumab combo recently beat standard care decisively on progression free survival, while cilta-cel, a CAR T cell therapy, treats the same patients in a single infusion with heavy logistics. In their 2026 analysis, a partitioned survival model compared the two using their trial data from a United States payer perspective.
The antibody combo added 2.094 quality adjusted life years over the cell therapy in the model, a real health gain, but at an additional cost of about 565,686 dollars. At the standard willingness to pay threshold of 150,000 dollars per quality adjusted year, the combo did not count as cost effective against cilta-cel. Scenario checks, including lower real world adherence, left the conclusion intact.
Catalog record
| CREATOR | Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |